when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

NOVARTIS · news · pharmadog

← back to NOVARTIS

News mentioning NOVARTIS

367 stories

Sep 2, 26STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and morestat

Sep 2, 26Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battlebiospace

Sep 2, 26Teva autoimmune antibody notches ph. 2 win in celiac diseasefiercebiotech

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Sep 2, 26Novartis inks $3.2B subcutaneous drug delivery deal with Alteogenfiercebiotech

Sep 1, 26Novartis says MS pill succeeds in two large studiesbiopharma dive

Sep 1, 26STAT+: 5 burning questions on Trump’s latest deals with drugmakersstat

Sep 1, 26STAT+: Novartis gets multiple sclerosis win with BTK inhibitorstat

Sep 1, 26STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and morestat

Sep 1, 269 midsize drugmakers climb aboard Trump’s MFN trainbiospace

Sep 1, 26Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety eventsbiospace

Sep 1, 26Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggestendpoints

Sep 1, 26Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also pausedendpoints

Sep 1, 26Recon: Trump announces new pricing deals with midsize biotechs; Novartis pauses CAR-T trials after patient deathsraps

Aug 31, 26Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concernsbiopharma dive

Aug 31, 26UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studiesfiercebiotech

Aug 31, 26A winner, a loser, and a mid-stage signal from a major cardiology research conferencestat

Aug 31, 26Electra aims to light up Nasdaq with IPO for phase 2/3 I&I pushfiercebiotech

Aug 31, 26STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapystat

Aug 29, 26STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?stat

Aug 29, 26#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo's failureendpoints

Aug 27, 26A year on from Big Pharma’s pull-back from the UK, has anything changed?fiercebiotech

Aug 26, 26Flagship’s ProFound partners with Gates Foundation in $35M preeclampsia target discovery pactfiercebiotech

Aug 26, 26Research into protein interactions sheds new light on causes of autismfiercebiotech

Aug 26, 26STAT+: New treatments for common cardiovascular risk factor near the market, with billions at stakestat

Aug 25, 26Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliencybiospace

Aug 24, 26News on AstraZeneca, Cytokinetics, Novartis — what to look out for at ESC 2026endpoints

Aug 21, 26Shareholder pressures Capricor; Lilly dives deeper into vaccinesbiopharma dive

Aug 20, 26Chutes & Ladders—Neumora shuffles leadership ahead of INDfiercebiotech

Aug 20, 26Scribe’s early-stage IPO standout defies biotech’s derisking trendbiospace

← prevpage 8 of 13next →